Want to see REPL full AI Analyst Report?
REPL Stock Chart & Stats
$2.17
$0.17(1.56%)
At close: 4:00 PM EST
$2.17
$0.17(1.56%)
Day’s Range― - ―
52-Week Range$1.50 - $13.24
Previous CloseN/A
Volume95.41K
Average Volume (3M)3.01M
Market Cap
$858.95M
Enterprise Value$475.48
Total Cash (Recent Filing)$268.89M
Total Debt (Recent Filing)$111.59M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.38
Shares Outstanding83,964,220
10 Day Avg. Volume2,703,037
30 Day Avg. Volume3,007,488
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)4.27
Price to Sales (P/S)0.00
P/FCF Ratio-2.49
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.00Price Target Upside545.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.17
Revenue Forecast (FY)$22.17M
Bulls Say, Bears Say
Bulls Say
Proprietary Immulytic Platform & PipelineReplimune’s Immulytic platform and multiple clinical-stage programs (RP1/2/3) represent a durable scientific moat in oncolytic immunotherapy. A multi-program pipeline spreads development risk across tumor types and combinations, preserving long-term optionality if one program succeeds commercially.
Regulatory Milestone: RP1 BLA AcceptanceFDA acceptance with a Class 1 designation and advisory committee increases structural visibility toward commercialization. This formal regulatory pathway materially raises the probability of eventual approval or clear decisioning, which is transformative for a pre-revenue biotech and affects multi-month planning and partnerships.
Relatively Modest LeverageLow absolute debt levels provide financial flexibility during extended R&D cycles, reducing interest burden and refinancing strain. For a clinical-stage company burning cash, modest leverage preserves capacity to fund development via equity or collaborations without compounding fixed liabilities over the medium term.
Bears Say
No Revenue And Widening LossesPersistent zero product revenue combined with escalating net losses is a structural risk: the business remains entirely dependent on R&D outcomes and external capital. Without commercialization or significant partnerships, continued losses erode optionality and increase the likelihood of dilutive financing in the medium term.
Severe Operating Cash BurnVery negative operating and free cash flow indicate the company cannot self-fund development. This durable cash burn necessitates near-term capital raises or partnerships, creating execution and dilution risk that constrains strategic choices and can delay or limit investment in additional trials or indications.
Shrinking Equity Base Increases Dilution RiskA materially reduced equity cushion diminishes balance-sheet resilience against setbacks. As losses persist, the smaller capital base raises the probability of further dilutive financings or conservative cuts to R&D spending, undermining long-term program advancement and shareholder value if approvals are delayed or negative.
Replimune Group News
REPL FAQ
What was Replimune Group’s price range in the past 12 months?
Replimune Group lowest stock price was $1.50 and its highest was $13.24 in the past 12 months.
What is Replimune Group’s market cap?
Replimune Group’s market cap is $858.95M.
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Replimune Group’s earnings last quarter?
Replimune Group released its earnings results on Jun 29, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.661 by -$0.099.
Is Replimune Group overvalued?
According to Wall Street analysts Replimune Group’s price is currently Undervalued.
Does Replimune Group pay dividends?
Replimune Group does not currently pay dividends.
What is Replimune Group’s EPS estimate?
Replimune Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Replimune Group have?
Replimune Group has 83,964,220 shares outstanding.
What happened to Replimune Group’s price movement after its last earnings report?
Replimune Group reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.661. Following the earnings report the stock price went down -3.697%.
Which hedge fund is a major shareholder of Replimune Group?
Currently, no hedge funds are holding shares in REPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Replimune Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (545.16% Upside)
$14.00 (545.16% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 132.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $474.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.71%
Trailing 12-Months
Company Description
Replimune Group
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$14.00
▲(545.16% Upside)
Technical Analysis
Anavex Life Sciences
―
Arcus Biosciences
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
3.49% Insiders
17.42% Mutual Funds
0.11% Other Institutional Investors
64.77% Public Companies and
Individual Investors